首页> 美国卫生研究院文献>American Journal of Human Genetics >Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations
【2h】

Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations

机译:与常染色体显性帕金森病有关的新型LRRK2突变的鉴定:欧洲人口共同创始人的证据。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Autosomal dominant parkinsonism has been attributed to pathogenic amino acid substitutions in leucine-rich repeat kinase 2 (LRRK2). By sequencing multiplex families consistent with a PARK8 assignment, we identified a novel heterozygous LRRK2 mutation. A referral sample of 248 affected probands from families with autosomal dominant parkinsonism was subsequently assessed; 7 (2.8%) were found to carry a heterozygous LRRK2 6055G→A transition (G2019S). These seven patients originate from the United States, Norway, Ireland, and Poland. In samples of patients with idiopathic Parkinson disease (PD) from the same populations, further screening identified six more patients with LRRK2 G2019S; no mutations were found in matched control individuals. Subsequently, 42 family members of the 13 probands were examined; 22 have an LRRK2 G2019S substitution, 7 with a diagnosis of PD. Of note, all patients share an ancestral haplotype indicative of a common founder, and, within families, LRRK2 G2019S segregates with disease (multipoint LOD score 2.41). Penetrance is age dependent, increasing from 17% at age 50 years to 85% at age 70 years. In summary, our study demonstrates that LRRK2 G2019S accounts for parkinsonism in several families within Europe and North America. Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis.
机译:常染色体显性帕金森病已归因于富含亮氨酸的重复激酶2(LRRK2)中的致病性氨基酸替代。通过测序符合PARK8分配的多重家族,我们确定了一个新的杂合LRRK2突变。随后评估了来自常染色体显性帕金森病家庭的248名受影响先证者的转诊样本;发现7个(2.8%)携带杂合的LRRK2 6055G→A过渡(G2019S)。这七名患者​​来自美国,挪威,爱尔兰和波兰。在来自相同人群的特发性帕金森病(PD)患者样本中,进一步的筛查确定了另外6名LRRK2 G2019S患者;在匹配的对照个体中未发现突变。随后,对13个先证者的42个家庭成员进行了检查; 22具LRRK2 G2019S替代品,7具PD诊断。值得注意的是,所有患者都具有共同祖先的祖先单体型,并且在家庭中,LRRK2 G2019S与疾病隔离(多点LOD评分2.41)。渗透率取决于年龄,从50岁时的17%增加到70岁时的85%。总而言之,我们的研究表明,LRRK2 G2019S可以解释欧洲和北美多个家庭的帕金森病。我们的工作突出了以下事实:一部分临床典型的迟发性PD病例具有遗传基础。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号